4-((4-Ethylpiperazin-1-yl)methyl)-1,3-dimesityl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate

Catalog No. :
ACGPWQ425
CAS No. :
1414700-17-6
Molecular Formula :
C28H41BF4N4
Molecular Weight :
520.47

IUPAC Name:4-((4-ethylpiperazin-1-yl)methyl)-1,3-dimesityl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate

4-((4-Ethylpiperazin-1-yl)methyl)-1,3-dimesityl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$261.00Login to see priceIn stockInquiry
250mg95%$454.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-((4-Ethylpiperazin-1-yl)methyl)-1,3-dimesityl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate
IUPAC Name4-((4-ethylpiperazin-1-yl)methyl)-1,3-dimesityl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate
Molecular FormulaC28H41BF4N4
Molecular Weight520.47
SMILESCC1=CC(C)=CC(C)=C1[N+]2=CN(C3=C(C)C=C(C)C=C3C)CC2CN4CCN(CC)CC4.F[B-](F)(F)F
InChI KeyXZCVCYLQSAIYOA-UHFFFAOYSA-N
Synonym4-((4-Ethylpiperazin-1-yl)methyl)-1,3-dimesityl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate;1H-Imidazolium, 4-[(4-ethyl-1-piperazinyl)methyl]-4,5-dihydro-1,3-bis(2,4,6-trimethylphenyl)-, tetrafluoroborate(1-) (1:1)
CAS No.1414700-17-6

Synthetic Route by SureRoute

1. ACGPWQ425 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGPWQ425 route product structure diagram
    ACGPWQ4251414700-17-6 In Stock
Inquiry

2. ACGPWQ425 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGPWQ425 route product structure diagram
    ACGPWQ4251414700-17-6 In Stock
Inquiry

Comments (0)